Transgenic Overexpression of Galectin-3 in Pancreatic β Cells Attenuates Hyperglycemia in Mice: Synergistic Antidiabetic Effect With Exogenous IL-33.
galectin-3
interleukin 33 (IL-33)
regulatory T cells (T reg)
type 1 diabetes mellitus (T1D)
β cells
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
05
2021
accepted:
27
09
2021
entrez:
22
11
2021
pubmed:
23
11
2021
medline:
23
11
2021
Statut:
epublish
Résumé
Galectin-3 (Gal-3) has diverse roles in inflammatory and autoimmune diseases. There is evidence that Gal-3 plays a role in both type 1 and type 2 diabetes. While the role of Gal-3 expression in immune cells invading the pancreatic islets in the experimental model of type 1 diabetes mellitus has been already studied, the importance of the overexpression of Gal-3 in the target β cells is not defined. Therefore, we used multiple low doses of streptozotocin (MLD-STZ)-induced diabetes in C57Bl/6 mice to analyze the effect of transgenic (TG) overexpression of Gal-3 in β cells. Our results demonstrated that the overexpression of Gal-3 protected β cells from apoptosis and attenuated MLD-STZ-induced hyperglycemia, glycosuria, and ketonuria. The cellular analysis of pancreata and draining lymph nodes showed that Gal-3 overexpression significantly decreased the number of pro-inflammatory cells without affecting the presence of T-regulatory cells. As the application of exogenous interleukin 33 (IL-33) given from the beginning of MLD-STZ diabetes induction attenuates the development of disease, by increasing the presence of regulatory FoxP3
Identifiants
pubmed: 34803672
doi: 10.3389/fphar.2021.714683
pii: 714683
pmc: PMC8602837
doi:
Types de publication
Journal Article
Langues
eng
Pagination
714683Informations de copyright
Copyright © 2021 Jovicic, Petrovic, Pejnovic, Ljujic, Miletic Kovacevic, Pavlovic, Jeftic, Djukic, Srejovic, Jakovljevic and Lukic.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int Immunopharmacol. 2019 May;70:9-15
pubmed: 30780005
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18425-30
pubmed: 16339897
J Biol Chem. 2000 Aug 4;275(31):23751-8
pubmed: 10823833
Immunol Lett. 2021 May;233:57-67
pubmed: 33753135
Immunology. 2008 Apr;123(4):547-54
pubmed: 18005036
Clin Exp Immunol. 2009 Feb;155(2):173-81
pubmed: 19128359
Glycoconj J. 2004;19(7-9):527-35
pubmed: 14758076
Front Endocrinol (Lausanne). 2020 Feb 07;11:30
pubmed: 32117058
J Biol Chem. 2002 Mar 1;277(9):6852-7
pubmed: 11724777
J Leukoc Biol. 2005 Nov;78(5):1127-35
pubmed: 16260586
J Clin Invest. 2011 Jan;121(1):442-5
pubmed: 21123946
Front Immunol. 2019 Feb 06;10:148
pubmed: 30787930
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6737-42
pubmed: 8692888
Immunol Rev. 2009 Jul;230(1):172-87
pubmed: 19594636
Glycoconj J. 2004;19(7-9):575-81
pubmed: 14758082
Immunol Rev. 2009 Jul;230(1):114-27
pubmed: 19594632
Adv Immunol. 2008;100:79-124
pubmed: 19111164
Adv Exp Med Biol. 2003;520:159-93
pubmed: 12613578
Nat Rev Dis Primers. 2017 Mar 30;3:17016
pubmed: 28358037
J Exp Med. 2012 Jan 16;209(1):51-60
pubmed: 22213807
Diabetes. 2008 May;57(5):1156
pubmed: 18443371
PLoS One. 2014 Nov 04;9(11):e111592
pubmed: 25369297
Nat Rev Endocrinol. 2019 Nov;15(11):635-650
pubmed: 31534209
Rev Endocr Metab Disord. 2003 Sep;4(3):291-9
pubmed: 14501180
Diabetologia. 2001 Dec;44(12):2115-33
pubmed: 11793013
Curr Protoc Immunol. 2007 Aug;Chapter 6:Unit 6.24
pubmed: 18432993
Clin Sci (Lond). 2012 Jun;122(11):487-511
pubmed: 22324470
Clin Immunol. 2009 Jan;130(1):83-8
pubmed: 18845486
Front Immunol. 2019 Aug 07;10:1762
pubmed: 31440233
J Leukoc Biol. 2001 Apr;69(4):555-64
pubmed: 11310841
Oncotarget. 2014 Oct 30;5(20):9992-10001
pubmed: 25393982
Cell. 2016 Nov 3;167(4):973-984.e12
pubmed: 27814523
Front Immunol. 2018 Nov 15;9:2646
pubmed: 30498495
J Cell Physiol. 2013 Jul;228(7):1568-76
pubmed: 23280610
Cancer Res. 1997 Dec 1;57(23):5272-6
pubmed: 9393748
Nat Protoc. 2009;4(11):1649-52
pubmed: 19876025
Diabetologia. 1997 Sep;40(9):1044-52
pubmed: 9300241
Neurobiol Dis. 2014 Feb;62:441-55
pubmed: 24184798
Cancer Res. 2006 Mar 15;66(6):3114-9
pubmed: 16540661
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
Biochim Biophys Acta. 2010 Feb;1800(2):181-9
pubmed: 19616076
Exp Biol Med (Maywood). 2015 Aug;240(8):1019-28
pubmed: 26142116
J Exp Med. 1996 Jan 1;183(1):67-76
pubmed: 8551245
J Immunol. 2014 Feb 15;192(4):1425-32
pubmed: 24446517
Clin Transl Immunology. 2020 Mar 16;9(3):e1122
pubmed: 32185024
Sci Rep. 2020 Apr 14;10(1):6405
pubmed: 32286393
Biochem Biophys Res Commun. 1991 Aug 15;178(3):913-20
pubmed: 1831356
Nat Rev Cancer. 2005 Jan;5(1):29-41
pubmed: 15630413
J Immunol. 2010 Aug 1;185(3):1959-67
pubmed: 20592279
J Immunol. 2009 Jan 15;182(2):1167-73
pubmed: 19124760
Diabetes. 2005 Dec;54 Suppl 2:S97-107
pubmed: 16306347
Curr Pharm Des. 2007;13(7):749-60
pubmed: 17346189